7月15日 - ** 医疗保健集团强生公司 （Johnson & Johnson） JNJ.N 的股价在盘前交易中下跌1.9%，报248.91美元
** 强生医疗技术部门第二季度销售额为89.3亿美元 (link)，低于分析师平均预期的89.7亿美元——路孚特（LSEG）汇编的数据
** 公司表示，该部门销售额受其Impella心脏泵 需求下滑影响，此前英国一项研究对在高风险冠状动脉手术中使用该泵提出了质疑
** 报告显示第二季度经调整后 每股 收益 为2.90美元，高于 分析师平均预期的2.85美元**
** 第二季度营收为253.1亿美元，高于分析师平均预期的250.5亿美元
** 强生公司将营收增长归功于免疫学药物Tremfya和癌症重磅药物Darzalex的强劲增长
** 截至上一交易日收盘，该股年内累计上涨22.7%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.